Novo Nordisk A/S (NVO)
Automate Your Wheel Strategy on NVO
With Tiblio's Option Bot, you can configure your own wheel strategy including NVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NVO
- Rev/Share 68.2827
- Book/Share 31.2062
- PB 15.1606
- Debt/Equity 0.857
- CurrentRatio 0.7386
- ROIC 0.3875
- MktCap 2122267952612.3438
- FreeCF/Share 16.8361
- PFCF 28.3938
- PE 20.0769
- Debt/Assets 0.2427
- DivYield 0.0222
- ROE 0.8124
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | NVO | BMO Capital Markets | Outperform | Market Perform | -- | $64 | April 17, 2025 |
| Upgrade | NVO | Kepler | Hold | Buy | -- | -- | March 13, 2025 |
| Downgrade | NVO | Stifel | Buy | Hold | -- | -- | March 3, 2025 |
| Initiation | NVO | Morgan Stanley | -- | Equal Weight | -- | -- | Feb. 12, 2025 |
| Upgrade | NVO | Bernstein | Underperform | Market Perform | -- | -- | Jan. 6, 2025 |
News
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
Published: March 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo Nordisk To Contact Him Directly To Discuss Their Options
Read More
Levi & Korsinsky Reminds Novo Nordisk A/S Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 - NVO
Published: March 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 11, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=135242&wire=1 or contact Joseph E. Levi, Esq.
Read More
NVO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Novo Nordisk A/S Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!
Published: March 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 11, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo Nordisk" or "the Company") (NYSE:NVO) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Novo Nordisk securities between November 2, 2022 and December 19, 2024, both dates inclusive (the "Class Period").
Read More
Levi & Korsinsky Notifies Shareholders of Novo Nordisk A/S(NVO) of a Class Action Lawsuit and an Upcoming Deadline
Published: March 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 11, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=135233&wire=1 or contact Joseph E. Levi, Esq.
Read More
Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
Published: March 11, 2025 by: Accesswire
Sentiment: Neutral
SAN FRANCISCO, CA / ACCESS Newswire / March 11, 2025 / National plaintiffs law firm Lieff Cabraser Heimann & Bernstein, LLP encourages investors in Novo Nordisk A/S. ("Novo" or the "Company") (NYSE:NVO) who purchased or otherwise acquired Novo securities between November 2, 2022, and December 19, 2024, inclusive (the "Class Period") to contact us immediately regarding a pending securities class action against Novo.
Read More
Levi & Korsinsky Reminds Novo Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 - NVO
Published: March 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 10, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=135051&wire=1 or contact Joseph E. Levi, Esq.
Read More
Novo Nordisk (NVO) Faces Securities Class Action After Weight Loss Therapy Trial Data Disappoints, Analyst Questions Trial's Design – Hagens Berman
Published: March 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, March 10, 2025 (GLOBE NEWSWIRE) -- Novo Nordisk A/S (NYSE: NVO) is facing a class-action lawsuit from investors who allege the pharmaceutical giant misled them about the prospects of its experimental obesity drug, CagriSema. Hagens Berman urges investors who purchased Novo Nordisk shares and suffered substantial losses to submit your losses now.
Read More
Levi & Korsinsky Reminds Novo Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 – NVO
Published: March 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, March 10, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit.
Read More
Novo Nordisk: CagriSema Disappoints Again
Published: March 10, 2025 by: Seeking Alpha
Sentiment: Negative
Novo Nordisk: CagriSema Disappoints Again
Read More
Why Novo Nordisk Stock Is Falling Today
Published: March 10, 2025 by: The Motley Fool
Sentiment: Negative
Shares of Novo Nordisk (NVO -8.70%) are tumbling on Monday. The company's stock lost 8.9% as of 10:10 a.m.
Read More
Novo Nordisk shares fall on weight-loss drug trial
Published: March 10, 2025 by: Fox Business
Sentiment: Negative
Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.
Read More
Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors
Published: March 10, 2025 by: MarketBeat
Sentiment: Neutral
Novo Nordisk A/S NYSE: NVO has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are no longer in short supply. This caused the United States Food and Drug Administration (FDA) to take semaglutide, the active ingredient in both, off the drug shortage list on February 21, 2025.
Read More
Novo Nordisk shares fall on weight loss drug trial results
Published: March 10, 2025 by: Proactive Investors
Sentiment: Negative
Novo Nordisk (NYSE:NVO) shares moved lower after the Danish drugmaker unveiled the latest trial results for its weight loss drug CagriSema. The Phase 3 trial, called Redefine 2, showed that CagriSema helped obese or overweight adults with type 2 diabetes reduce their weight by 15.7% after 68 weeks, compared to 3.1% with placebo.
Read More
Novo Nordisk Stock Drops on New Obesity Drug Finding. Eli Lilly Stands to Gain.
Published: March 10, 2025 by: Barrons
Sentiment: Negative
The Danish company said the average weight loss was 15.7% for the new drug, CagriSema. The expectation had been about 25%.
Read More
NVO Weight Loss Drug Disappoints, RDFN Acquisition, Airline Price Targets Slashed
Published: March 10, 2025 by: Schwab Network
Sentiment: Negative
Market weakness continued this morning, including in international companies like Novo Nordisk (NVO). Its next-gen weight loss drug trial results weren't enough to draw investors in.
Read More
NVO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Novo Nordisk A/S Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!
Published: March 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo Nordisk" or "the Company") (NYSE:NVO) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Novo Nordisk securities between November 2, 2022 and December 19, 2024, both dates inclusive (the "Class Period").
Read More
Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
Published: March 10, 2025 by: Accesswire
Sentiment: Neutral
SAN FRANCISCO, CA / ACCESS Newswire / March 10, 2025 / National plaintiffs law firm Lieff Cabraser Heimann & Bernstein, LLP encourages investors in Novo Nordisk A/S. ("Novo" or the "Company") (NYSE:NVO) who purchased or otherwise acquired Novo securities between November 2, 2022, and December 19, 2024, inclusive (the "Class Period") to contact us immediately regarding a pending securities class action against Novo.
Read More
Levi & Korsinsky Notifies Shareholders of Novo Nordisk A/S (NVO) of a Class Action Lawsuit and an Upcoming Deadline
Published: March 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit.
Read More
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action – NVO
Published: March 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between November 2, 2022 and December 19, 2024, both dates inclusive (the “Class Period”), of the important March 25, 2025 lead plaintiff deadline.
Read More
NVO, LLY and AMGN Forecast – Pharma Stocks Look Mixed in Premarket
Published: March 07, 2025 by: FXEmpire
Sentiment: Neutral
Three of the major pharma companies that I follow have shown a bit of a mixed move in the premarket hours, as the markets try to get a grip on the latest demand for GLP-1 and other medicines.
Read More
NVO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Published: March 07, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 7, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo Nordisk" or "the Company") (NYSE:NVO) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Novo Nordisk securities between November 2, 2022 and December 19, 2024, both dates inclusive (the "Class Period").
Read More
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Lawsuit Against Novo Nordisk A/S - NVO
Published: March 07, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 7, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo" or the "Company") (NASDAQ:NVO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
Novo Nordisk Lowers Wegovy Costs for Cash-Pay Patients, Stock Up 4%
Published: March 06, 2025 by: Zacks Investment Research
Sentiment: Neutral
NVO offers Wegovy at a discounted price of $499 per month, which is less than half of its listed price.
Read More
NVO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Novo Nordisk A/S Investors with Losses Have Opportunity to Lead Class Action Lawsuit!
Published: March 06, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 6, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo Nordisk" or "the Company") (NYSE:NVO) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Novo Nordisk securities between November 2, 2022 and December 19, 2024, both dates inclusive (the "Class Period").
Read More
Shareholders that lost money on Novo Nordisk A/S(NVO) should contact Levi & Korsinsky about pending Class Action - NVO
Published: March 06, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 6, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=134417&wire=1 or contact Joseph E. Levi, Esq.
Read More
Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
Published: March 06, 2025 by: Accesswire
Sentiment: Neutral
SAN FRANCISCO, CA / ACCESS Newswire / March 6, 2025 / National plaintiffs law firm Lieff Cabraser Heimann & Bernstein, LLP encourages investors in Novo Nordisk A/S. ("Novo" or the "Company") (NYSE:NVO) who purchased or otherwise acquired Novo securities between November 2, 2022, and December 19, 2024, inclusive (the "Class Period") to contact us immediately regarding a pending securities class action against Novo.
Read More
Novo Nordisk Drops Price of Weight-Loss Drug Wegovy for Some Patients Paying Out of Pocket
Published: March 05, 2025 by: Investopedia
Sentiment: Neutral
Novo Nordisk (NVO) is lowering the price of its popular weight-loss drug Wegovy for some patients paying out of pocket.
Read More
Novo Nordisk's Cheaper Wegovy Offering Is Bad News for Hims & Hers
Published: March 05, 2025 by: Barrons
Sentiment: Negative
The announcement comes weeks after the FDA declared that Wegovy is no longer in shortage.
Read More
NVO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Novo Nordisk A/S Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Published: March 05, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 5, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo Nordisk" or "the Company") (NYSE:NVO) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Novo Nordisk securities between November 2, 2022 and December 19, 2024, both dates inclusive (the "Class Period").
Read More
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 25, 2025 in Novo Nordisk A/S Lawsuit - NVO
Published: March 04, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 4, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=133930&wire=1 or contact Joseph E. Levi, Esq.
Read More
About Novo Nordisk A/S (NVO)
- IPO Date 1981-04-30
- Website https://www.novonordisk.com
- Industry Drug Manufacturers - General
- CEO Mr. Lars Fruergaard Jorgensen
- Employees 77406